tetano
Editor, Senior Moderator
Nat Commun
. 2021 Feb 26;12(1):1325.
doi: 10.1038/s41467-021-21553-1.
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Aakriti Gupta[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Mahesh V Madhavan[SUP] #[/SUP][SUP] 4 5 [/SUP], Timothy J Poterucha[SUP] 4 [/SUP], Ersilia M DeFilippis[SUP] 4 [/SUP], Jessica A Hennessey[SUP] 4 [/SUP], Bjorn Redfors[SUP] 4 5 6 [/SUP], Christina Eckhardt[SUP] 4 [/SUP], Behnood Bikdeli[SUP] 4 5 7 [/SUP], Jonathan Platt[SUP] 4 [/SUP], Ani Nalbandian[SUP] 4 [/SUP], Pierre Elias[SUP] 4 [/SUP], Matthew J Cummings[SUP] 4 [/SUP], Shayan N Nouri[SUP] 4 [/SUP], Matthew Lawlor[SUP] 4 [/SUP], Lauren S Ranard[SUP] 4 [/SUP], Jianhua Li[SUP] 4 [/SUP], Claudia Boyle[SUP] 4 [/SUP], Raymond Givens[SUP] 4 [/SUP], Daniel Brodie[SUP] 4 [/SUP], Harlan M Krumholz[SUP] 7 [/SUP], Gregg W Stone[SUP] 5 8 [/SUP], Sanjum S Sethi[SUP] 4 [/SUP], Daniel Burkhoff[SUP] 4 5 [/SUP], Nir Uriel[SUP] 4 [/SUP], Allan Schwartz[SUP] 4 [/SUP], Martin B Leon[SUP] 4 5 [/SUP], Ajay J Kirtane[SUP] 4 5 [/SUP], Elaine Y Wan[SUP] 9 [/SUP], Sahil A Parikh[SUP] 4 5 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1[SUP]st[/SUP] through May 12[SUP]th[/SUP], 2020 with study period ending on June 11[SUP]th[/SUP], 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36-0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.
. 2021 Feb 26;12(1):1325.
doi: 10.1038/s41467-021-21553-1.
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Aakriti Gupta[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Mahesh V Madhavan[SUP] #[/SUP][SUP] 4 5 [/SUP], Timothy J Poterucha[SUP] 4 [/SUP], Ersilia M DeFilippis[SUP] 4 [/SUP], Jessica A Hennessey[SUP] 4 [/SUP], Bjorn Redfors[SUP] 4 5 6 [/SUP], Christina Eckhardt[SUP] 4 [/SUP], Behnood Bikdeli[SUP] 4 5 7 [/SUP], Jonathan Platt[SUP] 4 [/SUP], Ani Nalbandian[SUP] 4 [/SUP], Pierre Elias[SUP] 4 [/SUP], Matthew J Cummings[SUP] 4 [/SUP], Shayan N Nouri[SUP] 4 [/SUP], Matthew Lawlor[SUP] 4 [/SUP], Lauren S Ranard[SUP] 4 [/SUP], Jianhua Li[SUP] 4 [/SUP], Claudia Boyle[SUP] 4 [/SUP], Raymond Givens[SUP] 4 [/SUP], Daniel Brodie[SUP] 4 [/SUP], Harlan M Krumholz[SUP] 7 [/SUP], Gregg W Stone[SUP] 5 8 [/SUP], Sanjum S Sethi[SUP] 4 [/SUP], Daniel Burkhoff[SUP] 4 5 [/SUP], Nir Uriel[SUP] 4 [/SUP], Allan Schwartz[SUP] 4 [/SUP], Martin B Leon[SUP] 4 5 [/SUP], Ajay J Kirtane[SUP] 4 5 [/SUP], Elaine Y Wan[SUP] 9 [/SUP], Sahil A Parikh[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33637713
- DOI: 10.1038/s41467-021-21553-1
Abstract
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1[SUP]st[/SUP] through May 12[SUP]th[/SUP], 2020 with study period ending on June 11[SUP]th[/SUP], 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36-0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.